Mandrola's Top 10 Cardiology Stories of 2021
Obesity drugs had a good year, the SGLT2 inhibitors stalled, and Entresto looks less impressive -- these are some of the takes from John Mandrola, MD, in his annual review of cardiology research.
Source: medscape.com